Machine-learning-guided screening validates 14 previously unreported drug–GPCR interactions
Chemical Space Neural Networks used network-neighborhood labels to predict drug–target interactions and were evaluated with a yeast biosensor screen of 3,773 compound–GPCR pairs (539 compounds and seven human GPCRs). The authors report 14 experimentally significant interactions with no prior literature/database evidence in the relevant chemical neighborhoods, tentatively linking some to adverse effects. This is an in-vitro receptor-screen discovery, not clinical proof of drug side effects.
Technology: Chemical Space Neural Networks (CSNN), neighborhood-to-prediction model using network homophily and graph neural networks with labels as features
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors report 14 experimentally significant interactions with no prior literature/database evidence in the relevant chemical neighborhoods, tentatively linking some to adverse effects.
- Still unknown: Yeast assay is a heterologous in-vitro system and does not establish physiological effects in humans. The article describes the 14 interactions as potentially linked to adverse effects, not confirmed clinical adverse events. Some assay limitations and false positives are discussed; precision for predicted positives is limited.
- AI role: Used chemical-neighborhood labels to prioritize/annotate compound–GPCR interactions; model outputs were compared with high-throughput yeast biosensor measurements to identify previously unreported hits.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12048553/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 85 of works of the same type, year and subfield (OpenAlex work metrics, 8 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.